Ignite Creation Date:
2024-07-17 @ 10:48 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06487247
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-06-27
Brief Title:
HEME Home Transfusion Program
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
Supportive Transfusion Program for Patients With Hematologic Malignancies A Cluster Randomized Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice ie HEME-Hospice compared to regular standard of care improves quality of life mood and end-of-life health care utilization for patients with hematologic malignancies
Detailed Description:
Lack of access to blood transfusions is a key barrier to timely hospice use for patients with blood cancers Refractory anemia and thrombocytopenia are common for patients with blood cancers and result in debilitating fatigue shortness of breath and bleeding Transfusions palliate these symptoms and improve quality of life QOL yet most hospices do not provide access to transfusions Patients are thus faced with the agonizing choice of preserving access to vital palliative transfusions versus accessing quality home-based hospice care Patients with blood cancers and their caregivers report that transfusions are vital for their quality of life and that access to transfusions is a key factor in deciding whether to opt for hospice care
The study team has thus developed a new model of care HEME-Hospice that provides access to palliative home transfusions to patients with hematologic malignancies who are enrolled in hospice The purpose of this study is to determine whether access to HEME-hospice versus usual care improves hospice enrollment rates quality of life QOL mood and end-of-life healthcare utilization for patients with hematologic malignancies as well as QOL and mood of their caregivers This study is a cluster randomized trial in which hematologic oncologists will be randomly assigned to access to HEME-Hospice versus usual care Participants in this study will have access to HEME-hospice or usual care based upon the strategy to which their hematologic oncologist has been assigned
The study team has thus developed a new model of care HEME-Hospice that provides access to palliative home transfusions to patients with hematologic malignancies who are enrolled in hospice The purpose of this study is to determine whether access to HEME-hospice versus usual care improves hospice enrollment rates quality of life QOL mood and end-of-life healthcare utilization for patients with hematologic malignancies as well as QOL and mood of their caregivers This study is a cluster randomized trial in which hematologic oncologists will be randomly assigned to access to HEME-Hospice versus usual care Participants in this study will have access to HEME-hospice or usual care based upon the strategy to which their hematologic oncologist has been assigned
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R37CA289639 | NIH | None | None |